secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001356576-25-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M
--------------------------------------------------------------------------------

- First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.
- Qelbree net sales $64.7M (+44% YoY); GOCOVRI net sales $30.7M (+16% YoY).
- ONAPGO (apomorphine infusion) launched in U.S. in April 2025 for Parkinson's motor fluctuations.
- Adjusted operating earnings (non-GAAP) increased 16% to $25.9M; full year 2025 guidance reaffirmed.
- Qelbree prescriptions grew 22%; March 2025 monthly Rx hit all-time high of 75,277.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000031/0001356576-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000031/supn-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer